Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
29 hedge funds and large institutions have $2.76M invested in Navidea Biopharmaceuticals Inc. in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 3 closing their positions.
6% less funds holding
Funds holding: 31 → 29 (-2)
12% less capital invested
Capital invested by funds: $3.13M → $2.76M (-$372K)
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
60% less call options, than puts
Call options by funds: $250K | Put options by funds: $619K
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
+$15.1K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.5K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$10.8K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$3.37K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.55K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$94.5K |
| 2 |
Two Sigma Investments
New York
|
-$59.8K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$37.9K |
| 4 |
ACM
Allred Capital Management
Dallas,
Texas
|
-$14.8K |
| 5 |
Morgan Stanley
New York
|
-$14.4K |
NAVB Hedge Fund Activity: Q3 2021 in Review
29 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q3 2021, worth a combined $2.76M — down 12% from $3.13M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of NAVB and 1 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 6 added.
The largest buyer was Group One Trading, adding an estimated $15.1K. The largest seller was Two Sigma Advisers, cutting an estimated $94.5K.
- 29 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q3 2021, down from 31 in Q2 2021.
- Funds reported $2.76M of Navidea Biopharmaceuticals Inc. stock for Q3 2021, down 12% quarter-over-quarter.
- 1 fund opened new Navidea Biopharmaceuticals Inc. positions in Q3 2021 and 3 closed out, a net change of -2 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q3 2021 was Group One Trading, an estimated $15.1K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q3 2021 was Two Sigma Advisers, an estimated $94.5K sold.
Based on aggregated 13F filings for Q3 2021.